1. Alzeca Bio is developing a platform technology to provide
a more accurate, lower cost diagnostic technology for
Alzheimer’s Disease. The platform is also being utilized to
reformulate Alzheimer’s therapies in order to be more
effective and less toxic.
Week 9

2. Team
- Alzeca CEO and CoFounder
- Previous start-up/life
science, VC, I-Banking
experience
- Molecular
Oncologist
- VC experience
- MBA, Stanford
- Internal Medicine
- Health Services
Researcher
- UCSF Faculty
- Senior
development
process engineer
- Pharma
Consultant
- Mentor
- R&D Consultant
- Ph.D & Post-Doc, UCSF

3. LaunchPad Centr al
Ke y Par t ne r s
Ke y Activitie s
Valu e Pr o p o sit io n s
Cu st o m e r
Re lat io n sh ip s
Cu st o m e r Se g m e n ts
 Ph a r m a ce u t ica l
 Va lid a t e t h e
 (D x) To o l t o e va lu a t e
 In s t it u t io n s
Co m p a n ie s
d ia g n o s t ic t e ch n o lo g y
e n d p o in t in clin ica l
co n d u ct in g clin ica l
in in vivo a n im a l
t r ia ls
t r ia ls
 FD A
 Co n t r a s t Ag e n t
M a n u fa ct u r e r s
 Im a g in g Eq u ip m e n t
s t u d ie s a n d h u m a n
 Sh o w h ig h
 (D x) Accu r a t e ly
 Ph a r m a ce u t ica l
s e le ct in g p a t ie n t s fo r
s t u d ie s .
Co m p a n ie s
clin ica l t r ia ls
 Co n t r a s t Ag e n t
r e s o lu t io n im a g in g a n d
m a k e q u a n t it a t ive
Ke y Re so u r ce s
M a n u fa ct u r e r s
 (D x) Pr o vid in g e a r ly
d ia g n o s is t o s u s p e ct e d
 Aca d e m ic la b s a n d
p h a r m a co m p a n ie s t o
r e fo r m u la t e AD
t h e r a p ie s
 CRO s
M a n u fa ct u r e r s
Ch an n e ls
Alz h e im e r ' s p a t ie n t s
 Ca p it a l
 Exclu s ive r ig h t s t o
in t e lle ct u a l p r o p e r t y
a n d k n o w le d g e o f
 (D x) Ea s ie r a cce s s
 (D x) D ir e ct t o
fo r p a t ie n t s
pha rma groups
r u n n in g clin ica l t r ia ls
 H o s p it a ls
 CRO s
 (Rx) Pr o vid in g m o r e
e ffe ct ive t h e r a p e u t ics
 (Rx) Lice n s in g t o
t o Alz h e im e r 's p a t ie n t s
t r a d e s e cr e t s
 Alz h e im e r ' s Pa t ie n t s
p h a r m a g r o u p s fo r
 R& D Pe r s o n n e l
t h e r a p e u t ic
 Re s e a r ch Fa cilit ie s
r e fo r m u la t io n
Co st St r u ct u r e
 R& D /O p e r a t io n a l Pe r s o n n e l
 In t e lle ct u a l Pr o p e r t y
 Co n s u m a b le s (m a t e r ia ls t o m a k e p r o d u ct s )
 Re s e a r ch An im a ls
 Re s e a r ch Fa cilit ie s
 M is ce lla n e o u s (Acco u n t in g , Tr a ve l, Co n fe r e n ce s )
Re ve n u e Str am x) Co n t r a s t Ag e n t
e (D s
 To o l fo r q u a n t it a t ive b io m a r k e r m e a s u r e m e n t t o m e a s u r e
t h e r a p e u t ic e ffica cy
 To o l fo r p a t ie n t s e le ct io n in clin ica l t r ia ls
 Se llin g Th e r a p e u t ics t o Alz h e im e r ' s Pa t ie n t s
 Se llin g d ia g n o s t ic a g e n t t o s u s p e ct e d Alz . p a t ie n t s
 Lice n s in g d e live r y p la t fo r m t o p h a r m a co m p a n ie s
d e ve lo p in g Alz . d r u g s
Li c e n se d fr o m b u si n e ssm o d e l g e n e r a t i o n .c o m u n d e r a Cr e a t i ve Co m m o n s At t r i b u t i o n -S h a r e Al i ke 3 .0 Un p o r t e d Li c e n se

4. What We Thought (Rx) : Failed
compounds can be reborn

5. What We Did
Informal Partners
Pharma

6. What We Learned: Just Because
You Can Does Not Mean You
should

7. What we Thought (Dx)

8. What We Did
Informal Partners
Pharma
Imaging

9. What We Learned

10. What’s Next
• Focus on Dx opportunities (tau in addition to
amyloid)
• Better understand reimbursement

11. Next Steps…
• Review our recent preclinical data with KOLs,
pharma, and imaging companies to determine
additional needs
• Elucidate inflection points for them to endorse,
invest, and partner in early stage clinical studies
• establish budget for each
• Assess other AD diagnostics and treatments in
development
• Clarify and disseminate competitive advantages
of ADx

12. Partnering/Customers Lay of the Lands (Populate this)
Pre-clinical research tool
Rodent PoC
Primate PoC
Phase 1 PoC
Randomized
phase 2
Randomized
phase 3
Patient Stratification for
clinical trials
(Novel) Drug reformulation

13. Lessons Learned about Cost, Key Resources, and Activities
Hypothesis
Experiments
Results
Affordable to patients
Talk to KOL,
CMS
consultants
1) ADx would be affordable and
some patients would self
pay.
2) CMS covers MRI w/o
contrast agent.
Key
Capital, patents, R&D
Resources personnel, facilities,
development partners.
Talk to pharma
companies,
KOL, patent
lawyers
1) True.
2) CMS consultant.
3) FDA is a key
partner/resource.
Activities
Talk to pharma
companies,
CROs, KOLs,
Regulatory
1) True.
2) Each company has its own
unique criteria.
Cost
Validate technology,
prove safety in humans,
regulatory pathway,
demonstrate high
resolution.

14. What is best route to your destination?

15. Go out and talk to people!

16. It is about working your network

17. Every customer is unique

18. Attend Conferences

19. What do experts think?

20. Will people invest now?

21. product

22. Can you get there on your own?

23. Who is that strategic partner?

24. How do get to the deal?

25. Does your MVP work?

26. Is it going to be too expensive for the
patient?

27. Not only lower cost, Higher Resolution

28. Use it in pre-clinical testing first

29. That miracle drug!